David M. Epstein, Ph.D. served as the CEO of Black Diamond Therapeutics, Inc. from January 2020 until September 2023. With a strong background in biotechnology and a Ph.D. in a related field, he brought a solid scientific perspective to the...

David M. Epstein, Ph.D. served as the CEO of Black Diamond Therapeutics, Inc. from January 2020 until September 2023. With a strong background in biotechnology and a Ph.D. in a related field, he brought a solid scientific perspective to the helm of the company. During his tenure, Dr. Epstein oversaw important milestones in drug development, particularly with innovative therapies. After stepping down, he remained a board member, indicating his continued interest in the company's future. Interestingly, his compensation varied over his years as CEO, peaking in 2021 when he earned over $5 million, driven mainly by stock options. His separation agreement included significant severance pay, reflecting his influence and contributions. David's journey through significant fluctuations in compensation and insider trading highlights the ups and downs typical in biotechnology firms, where the stakes are high, and outcomes can be unpredictable. From multiple millions in stock trades to a strategic departure, his career paints a picture of a passionate leader in the fast-paced biotech world.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Black Diamond Therapeutics, Inc. CEOs

B

David M. Epstein, Ph.D.

Ex-CEO of Black Diamond Therapeutics, Inc.

Education

Ph.D. in a relevant field

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1973 - 52 years ago

CEO of Black Diamond Therapeutics, Inc. for

3 years 8 months (Jan 2020 - Sep 2023)

Previous Experience

Former CEO of a biotechnology company

Rivals

Competitors/colleagues of David M. Epstein, Ph.D.

Holdings

See how much did David M. Epstein, Ph.D. make over time.

During his time at Black Diamond Therapeutics, Dr. Epstein was involved in insider trading activities that showed a good deal of fluctuation. For instance, in early 2020, he reported substantial trades, with one trade valued at $30.1 million. This was...

During his time at Black Diamond Therapeutics, Dr. Epstein was involved in insider trading activities that showed a good deal of fluctuation. For instance, in early 2020, he reported substantial trades, with one trade valued at $30.1 million. This was a strong indicator of his confidence in the company’s direction at that time. However, like many in the biotech sector, his holdings saw ups and downs. By early 2021, his trades averaged between $6 million and $20 million monthly, reflecting the volatile nature of the biotech market. After a peak in wealth tied to stock holdings in 2021, trading activity started to taper down as he approached his departure in 2023. It tells a compelling story of someone deeply intertwined with the fortunes of a pioneering biotech firm.

Total Stock Sold

$1.67M

BDTX

$1.67M

73,000 BDTX shares

What if they kept their stock?

If David M. Epstein, Ph.D. didn't sell their stock, today they would have:
Extra BDTX73,000 shares worth $1.90M.
This is 13.19% and $220.78K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of David M. Epstein, Ph.D..

BDTX

$167.50K

BDTX at $6.70/share

Jun 27, 2023

Sale

BDTX

$376.73K

BDTX at $31.39/share

Jan 4, 2021

Sale

BDTX

$396.53K

BDTX at $33.04/share

Dec 1, 2020

Sale

BDTX

$378.05K

BDTX at $31.50/share

Nov 2, 2020

Sale

BDTX

$363.96K

BDTX at $30.33/share

Oct 1, 2020

Sale

Compensation History

See how much did David M. Epstein, Ph.D. make over time.

David M. Epstein's compensation varied significantly during his time as CEO of Black Diamond Therapeutics. In 2023, his total compensation was around $2 million, which included a cash bonus outlined in his separation agreement due to his early resignation. Before that, in 2021, he earned about $5 million, largely driven by stock options. This pattern highlights the pay-for-performance model common in biotech, where leaders often tie their income directly to the company’s market performance. His separation package further illustrated this, encompassing severance and vacation pay, indicating that exit strategies are as much a part of executive compensation as are annual salaries and bonuses.

Year

2023

Total Compensation

$2.02M

Salary

$412.30K

Board Justification

The compensation philosophy is based on a pay-for-performance model, aligning executive compensation with company performance and market benchmarks.

Bonus

$1.05M

Board Justification

Dr. Epstein's separation agreement provided him with a cash amount equal to his target bonus for 2023, as he resigned prior to the payment date.

Other

$557.39K

Board Justification

This includes severance and vacation payout amounts of $489,909 and $48,141, respectively.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

The performance metrics for determining compensation include achievement of company and individual performance goals.

Other Black Diamond Therapeutics, Inc. CEOs

Here are other CEOs of Black Diamond Therapeutics, Inc.

Mark A. Velleca, M.D., Ph.D.

CEO of Black Diamond Therapeutics, Inc.

September 2023 - Present